1. Home
  2. ING vs SNY Comparison

ING vs SNY Comparison

Compare ING & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ING Group N.V.

ING

ING Group N.V.

HOLD

Current Price

$32.82

Market Cap

89.9B

Sector

Finance

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$42.73

Market Cap

104.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ING
SNY
Founded
1991
1994
Country
Netherlands
France
Employees
60000
74846
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.9B
104.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ING
SNY
Price
$32.82
$42.73
Analyst Decision
Buy
Buy
Analyst Count
1
5
Target Price
N/A
$58.00
AVG Volume (30 Days)
5.0M
4.1M
Earning Date
04-30-2026
04-23-2026
Dividend Yield
4.50%
3.47%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.59
$3.49
Revenue Next Year
$6.55
$6.10
P/E Ratio
$11.40
$6.14
Revenue Growth
N/A
N/A
52 Week Low
$22.40
$40.89
52 Week High
$32.40
$52.68

Technical Indicators

Market Signals
Indicator
ING
SNY
Relative Strength Index (RSI) 67.96 47.70
Support Level $27.82 $42.64
Resistance Level N/A $48.90
Average True Range (ATR) 0.41 0.82
MACD 0.12 0.06
Stochastic Oscillator 100.00 55.93

Price Performance

Historical Comparison
ING
SNY

About ING ING Group N.V.

The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions, ING has built up a global footprint. The 2008 financial crisis forced ING to seek government support—a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market-leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: